为您找到相关结果约500个

你是不是要搜索 期刊HR-MDS合并AML-TD 点击跳转

Randomized, multicenter, phase II trial of clofarabine/ARA-C (CLARAC) or of flamsa treatment in high risk AMLor advanced MDS scheduled for allogeneic SCT

Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULT PATIENTS WITH IDH MUTATED AML AND MDS: A STUDY FROM

REAL-WORLD AZACITIDINE USE DOES NOT REPLICATE AZA-001 RESULTS IN HIGHER-RISK MDS/LOW-BLAST COUNT AML:

Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS

phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AMLand MDS patients (vol 4, pg 5580, 2020)

Mutation-Driven Therapy in MDS

Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS

Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood AcuteMyeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group

patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party

Post-Transplant Low-Dose Azacitidine Can Improve Overall Survival in AML/MDS Patients and is Associated

Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation of AML in CR andMDS-a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse

The MDS genomics-prognosis symbiosis

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related

为您找到相关结果约500个

共500条页码: 34/34页15条/页